Evidence map›Paper›PMID 40586816›Full record

ReviewEuropean radiology2026

Updated ESUR Guidelines for Endometrial Cancer: integrating MRI with the 2023 FIGO Staging Revolution.

Stephanie Nougaret, Evis Sala, Yulia Lakhman, Elisabeth Sadowski, Aradhana M Venkatesan, Andrea Rockall, Isabelle Thomassin-Naggara, Aki Kido, Nishat Bharwani, Teresa Margarida Cunha and 7 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Guideline
  2. Review
  3. Article
  4. Endometrial Cancer: A Daily Clinical Practice Guide for Radiologists.Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Stephanie NougaretDepartment of Radiology, Montpellier Cancer Institute, University of Montpellier, 208 av des Apothicaires, 34090, Montpellier, France. stephanienougaret@free.fr.ORCID http://orcid.org/0000-0002-6398-8648
Evis SalaDipartimento Diagnostica per Immagini e Radioterapia Oncologica, Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Yulia LakhmanDepartment of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Elisabeth SadowskiDepartments of Radiology and Obstetrics and Gynecology, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA.
Aradhana M VenkatesanDepartment of Abdominal Imaging, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Andrea RockallDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, London, UK.
Isabelle Thomassin-NaggaraRadiology Imaging and Interventional Radiology Specialized Department (IRIS), Tenon Hospital, Public Hospital of Paris, Paris, France.
Aki KidoRadiology department, Toyama University, Toyoma, Japan.
Nishat BharwaniDepartment of Imaging, Imperial College Healthcare NHS Trust, London, UK.
Teresa Margarida CunhaDepartment of Radiology, Instituto Português de Oncologia de Lisboa Francisco Gentil, Lisbon, Portugal.
Rosemarie ForstnerDepartment of Radiology, University Hospital of Salzburg, PMU, Salzburg, Austria.
Pamela Causa-AndrieuDepartment of Radiology, Mayo Clinic, Rochester, MN, USA.
Giacomo AvesaniDipartimento Diagnostica per Immagini e Radioterapia Oncologica, Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Ingfrid HaldorsenDepartment of Radiology, Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Alejandra MartinezInstitut Universitaire du Cancer Toulouse Oncopole, Institut Claudius Regaud, Toulouse, France.
Lucia Manganaro *Department of Radiological, Oncological and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Stefania Rizzo *Imaging Institute of Southern Switzerland (IIMSI), Ente Ospedaliero Cantonale (EOC), via Tesserete 46, 6900, Lugano, Switzerland.

Funding

HORIZON EUROPE European Research Council 101077710
6 · The paper itself

Abstract

objectivesTo summarize the key updates introduced in the 2023 International Federation of Gynecology and Obstetrics (FIGO) classification for endometrial cancer (EC), and to highlight the role of MRI in aligning with these changes for improved staging and patient management. MATERIALS AND

methodsA review of the updated 2023 FIGO classification, which integrates molecular profiling and histopathological criteria, was conducted. Additionally, the revised European Society of Urogenital Radiology (ESUR) MRI recommendations were analyzed to assess their alignment with the new FIGO framework, focusing on their role in evaluating myometrial invasion (MI) and cervical stromal involvement.

resultsThe updated FIGO classification incorporates molecular data to refine risk stratification and staging accuracy. MRI continues to play a pivotal role in distinguishing between stages, mapping disease extent, and guiding surgical planning. The updated ESUR recommendations emphasize standardized MRI protocols, particularly the use of multiphase contrast-enhanced imaging, to improve diagnostic confidence in assessing MI.

conclusionThe integration of molecular classification into FIGO staging, supported by standardized and advanced MRI protocols as recommended by ESUR, enhances the management of endometrial cancer. KEY POINTS: Question The 2023 FIGO update integrates molecular profiling into endometrial cancer staging, requiring MRI adaptations to improve accuracy in assessing disease extent, including myometrial invasion. Findings Updated ESUR MRI guidelines emphasize multiphase contrast-enhanced imaging, structured reporting, and integration with FIGO 2023 classification, enhancing diagnostic precision for staging and treatment planning. Clinical relevance Standardized MRI protocols aligned with FIGO 2023 system improve endometrial cancer staging, guiding optimal surgical and therapeutic strategies, reducing diagnostic variability, and enhancing patient outcomes through individualized risk stratification and personalized treatment.

Indexed as

Endometrial NeoplasmsMagnetic Resonance ImagingEuropeFemaleHumansNeoplasm InvasivenessNeoplasm StagingPractice Guidelines as TopicSocieties, MedicalDiagnostic molecular pathologyEndometrial cancerGynecologic neoplasmMagnetic resonance imagingPractice guidelines

Identifiers

PMID40586816

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.